161 related articles for article (PubMed ID: 31098630)
1. Treatment duration of pivmecillinam in men, non-pregnant and pregnant women for community-acquired urinary tract infections caused by Escherichia coli: a retrospective Danish cohort study.
Boel JB; Jansåker F; Hertz FB; Hansen KH; Thønnings S; Frimodt-Møller N; Knudsen JD
J Antimicrob Chemother; 2019 Sep; 74(9):2767-2773. PubMed ID: 31098630
[TBL] [Abstract][Full Text] [Related]
2. Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study.
Bollestad M; Grude N; Solhaug S; Raffelsberger N; Handal N; Nilsen HS; Romstad MR; Emmert A; Tveten Y; Søraas A; Jenum PA; Jenum S; Møller-Stray J; Weme ET; Lindbaek M; Simonsen GS;
J Antimicrob Chemother; 2018 Sep; 73(9):2503-2509. PubMed ID: 29982514
[TBL] [Abstract][Full Text] [Related]
3. Microbial risk factors for treatment failure of pivmecillinam in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
Syre H; Hetland MAK; Bernhoff E; Bollestad M; Grude N; Simonsen GS; Löhr IH
APMIS; 2020 Mar; 128(3):232-241. PubMed ID: 31755584
[TBL] [Abstract][Full Text] [Related]
4. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
Jansåker F; Frimodt-Møller N; Sjögren I; Dahl Knudsen J
J Antimicrob Chemother; 2014 Mar; 69(3):769-72. PubMed ID: 24107388
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections - a randomized, double-blinded, placebo-controlled clinical trial study protocol.
Jansåker F; Frimodt-Møller N; Bjerrum L; Dahl Knudsen J
BMC Infect Dis; 2016 Dec; 16(1):727. PubMed ID: 27905884
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial resistance in community-acquired urinary tract infections in Paris in 2015.
Chervet D; Lortholary O; Zahar JR; Dufougeray A; Pilmis B; Partouche H
Med Mal Infect; 2018 May; 48(3):188-192. PubMed ID: 29054298
[TBL] [Abstract][Full Text] [Related]
7. Pulsed-field gel electrophoresis typing of Escherichia coli strains from samples collected before and after pivmecillinam or placebo treatment of uncomplicated community-acquired urinary tract infection in women.
Ejrnaes K; Sandvang D; Lundgren B; Ferry S; Holm S; Monsen T; Lundholm R; Frimodt-Moller N
J Clin Microbiol; 2006 May; 44(5):1776-81. PubMed ID: 16672406
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for extended-spectrum β-lactamase-producing Escherichia coli urinary tract infection in the community in Denmark: a case-control study.
Søgaard M; Heide-Jørgensen U; Vandenbroucke JP; Schønheyder HC; Vandenbroucke-Grauls CMJE
Clin Microbiol Infect; 2017 Dec; 23(12):952-960. PubMed ID: 28377310
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Iversen A; Kalin M; Giske CG
Microb Drug Resist; 2012 Apr; 18(2):189-92. PubMed ID: 22204597
[TBL] [Abstract][Full Text] [Related]
11. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project.
Ferry SA; Holm SE; Stenlund H; Lundholm R; Monsen TJ
Scand J Prim Health Care; 2007 Mar; 25(1):49-57. PubMed ID: 17354160
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological factors associated with ESBL- and non ESBL-producing E. coli causing urinary tract infection in general practice.
Hertz FB; Schønning K; Rasmussen SC; Littauer P; Knudsen JD; Løbner-Olesen A; Frimodt-Møller N
Infect Dis (Lond); 2016; 48(3):241-5. PubMed ID: 26523346
[TBL] [Abstract][Full Text] [Related]
13. Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men.
Montelin H; Forsman KJ; Tängdén T
PLoS One; 2019; 14(1):e0211098. PubMed ID: 30682092
[TBL] [Abstract][Full Text] [Related]
14. [Prescriptions of a new antibiotic following treatment with sulfamethizole or pivmecillinam].
Bjerrum L; Dessau RB; Hallas J
Ugeskr Laeger; 2003 Sep; 165(39):3732-5. PubMed ID: 14558387
[No Abstract] [Full Text] [Related]
15. Risk factors for community acquired pediatric urinary tract infection with extended-spectrum-β-lactamase Escherichia coli - A case-control study.
Collingwood JD; Wang L; Aban IB; Yarbrough AH; Boppana SB; Dangle PP
J Pediatr Urol; 2023 Feb; 19(1):129.e1-129.e7. PubMed ID: 36344365
[TBL] [Abstract][Full Text] [Related]
16. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
[TBL] [Abstract][Full Text] [Related]
17. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859
[TBL] [Abstract][Full Text] [Related]
18. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
[TBL] [Abstract][Full Text] [Related]
19. Non-Escherichia coli versus Escherichia coli community-acquired urinary tract infections in children hospitalized in a tertiary center: relative frequency, risk factors, antimicrobial resistance and outcome.
Marcus N; Ashkenazi S; Yaari A; Samra Z; Livni G
Pediatr Infect Dis J; 2005 Jul; 24(7):581-5. PubMed ID: 15998996
[TBL] [Abstract][Full Text] [Related]
20. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial.
Vik I; Bollestad M; Grude N; Bærheim A; Damsgaard E; Neumark T; Bjerrum L; Cordoba G; Olsen IC; Lindbæk M
PLoS Med; 2018 May; 15(5):e1002569. PubMed ID: 29763434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
